Acumen plans presentation of Phase 2 sabirnetug trial baseline data at CTAD

Bitget2026/10/22 11:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Acumen Pharmaceuticals will present three posters on its Phase 2 ALTITUDE-AD trial of sabirnetug for early Alzheimer’s disease.
Presentations are scheduled for Nov. 16-17, 2026, at the Clinical Trials on Alzheimer’s Disease conference in Boston, running Nov. 16-19.
The posters will cover preliminary participant baseline characteristics, treatment expectations and motivations, and care partners’ experiences.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610220730PRIMZONEFULLFEED9850829) on October 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Acumen plans presentation of Phase 2 sabirnetug trial baseline data at CTAD

You may also like

Crypto prices